CN118667019A - 针对人tim-3的单克隆抗体 - Google Patents

针对人tim-3的单克隆抗体 Download PDF

Info

Publication number
CN118667019A
CN118667019A CN202410802940.6A CN202410802940A CN118667019A CN 118667019 A CN118667019 A CN 118667019A CN 202410802940 A CN202410802940 A CN 202410802940A CN 118667019 A CN118667019 A CN 118667019A
Authority
CN
China
Prior art keywords
seq
antibody
antigen
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410802940.6A
Other languages
English (en)
Chinese (zh)
Inventor
臧兴兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of CN118667019A publication Critical patent/CN118667019A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202410802940.6A 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体 Pending CN118667019A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862720234P 2018-08-21 2018-08-21
US62/720,234 2018-08-21
CN201980037800.1A CN112566936B (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体
PCT/US2019/047573 WO2020041520A1 (en) 2018-08-21 2019-08-21 Monoclonal antibodies against human tim-3

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980037800.1A Division CN112566936B (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体

Publications (1)

Publication Number Publication Date
CN118667019A true CN118667019A (zh) 2024-09-20

Family

ID=69591459

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410802940.6A Pending CN118667019A (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体
CN201980037800.1A Active CN112566936B (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体
CN202410802960.3A Pending CN118667020A (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980037800.1A Active CN112566936B (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体
CN202410802960.3A Pending CN118667020A (zh) 2018-08-21 2019-08-21 针对人tim-3的单克隆抗体

Country Status (13)

Country Link
US (2) US12134645B2 (enExample)
EP (1) EP3841125A4 (enExample)
JP (2) JP7543247B2 (enExample)
KR (1) KR20210045999A (enExample)
CN (3) CN118667019A (enExample)
AU (1) AU2019325558A1 (enExample)
BR (1) BR112021003018A2 (enExample)
CA (1) CA3108879A1 (enExample)
IL (1) IL280757A (enExample)
MX (1) MX2020013428A (enExample)
NZ (1) NZ770219A (enExample)
SG (1) SG11202012148RA (enExample)
WO (1) WO2020041520A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118667019A (zh) * 2018-08-21 2024-09-20 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
WO2021175191A1 (zh) * 2020-03-02 2021-09-10 信达生物制药(苏州)有限公司 抗tim-3抗体及其用途
WO2022223048A1 (en) * 2021-04-23 2022-10-27 Suzhou Neologics Bioscience Co. , Ltd. Tim-3-targetting antibodies and uses thereof
EP4494654A1 (en) 2022-03-14 2025-01-22 Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
WO2023174408A1 (zh) * 2022-03-18 2023-09-21 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-l1抗体的药物组合
CN119053343A (zh) 2022-05-13 2024-11-29 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-1抗体的药物组合
CN119789867A (zh) * 2022-09-06 2025-04-08 正大天晴药业集团股份有限公司 结合tim-3的抗体与结合pd-1的抗体的药物组合
CN120752053A (zh) * 2023-03-03 2025-10-03 正大天晴药业集团南京顺欣制药有限公司 含抗tim-3抗体的药物组合
WO2025056005A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 抗tim-3抗体的药物组合物及用途
WO2025056014A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2005033144A2 (en) 2003-10-03 2005-04-14 Brigham And Women's Hospital Tim-3 polypeptides
AU2004292180A1 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
KR101188117B1 (ko) 2005-03-31 2012-10-09 바이오메딕스 인코포레이티드 항ｃｄ20 모노클로날 항체
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2162471A1 (en) 2007-06-08 2010-03-17 Université de la Méditerranée Compositions and methods for treating pancreatic tumors
BR112012020101A2 (pt) 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
KR101846590B1 (ko) * 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
US9321833B2 (en) 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
US10053511B2 (en) * 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
SG11201808724SA (en) 2016-04-12 2018-11-29 Symphogen As Anti-tim-3 antibodies and compositions
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
TWI769174B (zh) 2016-08-26 2022-07-01 英屬開曼群島商百濟神州有限公司 抗tim-3抗體及其用途
MX2019005116A (es) * 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
CN118667019A (zh) * 2018-08-21 2024-09-20 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体

Also Published As

Publication number Publication date
CN112566936A (zh) 2021-03-26
CA3108879A1 (en) 2020-02-27
US20210198357A1 (en) 2021-07-01
JP2021534735A (ja) 2021-12-16
SG11202012148RA (en) 2021-01-28
EP3841125A1 (en) 2021-06-30
IL280757A (en) 2021-04-29
JP2024119853A (ja) 2024-09-03
EP3841125A4 (en) 2022-05-11
CN118667020A (zh) 2024-09-20
US12134645B2 (en) 2024-11-05
AU2019325558A1 (en) 2020-12-17
BR112021003018A2 (pt) 2021-05-11
JP7543247B2 (ja) 2024-09-02
MX2020013428A (es) 2021-07-16
US20250034248A1 (en) 2025-01-30
WO2020041520A1 (en) 2020-02-27
CN112566936B (zh) 2024-07-12
KR20210045999A (ko) 2021-04-27
NZ770219A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
US20250034248A1 (en) Monoclonal antibodies against human tim-3
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
EP4155318A1 (en) Bispecific antibody and use thereof
JP2022529340A (ja) ヒトｃｄ４７を標的とする抗体
US12145989B2 (en) Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
EP4292610A1 (en) Variant antibodies that bind gamma-delta t cell receptors
JP2023508366A (ja) 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法
RU2777336C1 (ru) Моноклональные антитела к tim-3 человека
HK40043135A (en) Monoclonal antibodies against human tim-3
US20250109204A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
HK40043135B (zh) 针对人tim-3的单克隆抗体
KR20250110219A (ko) 표피 성장 인자 수용체 변이체 iii 항체
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
CN120380019A (zh) 抗cd24抗体及其用途
CN119698435A (zh) 抗ilt4抗体及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination